Outset Medical (OM) to Release Earnings on Wednesday

Outset Medical (NASDAQ:OM) is projected to post its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect Outset Medical to post earnings of ($0.42) per share and revenue of $28.47 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Outset Medical Stock Up 1.2 %

Shares of Outset Medical stock opened at $0.79 on Wednesday. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12. The business’s 50 day simple moving average is $1.00 and its 200-day simple moving average is $0.94. The stock has a market capitalization of $42.68 million, a price-to-earnings ratio of -0.29 and a beta of 2.01. Outset Medical has a twelve month low of $0.44 and a twelve month high of $5.22.

Analysts Set New Price Targets

Separately, Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 price target on shares of Outset Medical in a research report on Tuesday, January 7th.

Insider Transactions at Outset Medical

In related news, CEO Leslie Trigg sold 65,236 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total value of $52,188.80. Following the sale, the chief executive officer now directly owns 895,580 shares in the company, valued at $716,464. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel John L. Brottem sold 32,930 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total value of $26,344.00. Following the completion of the sale, the general counsel now owns 181,188 shares in the company, valued at approximately $144,950.40. This represents a 15.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 282,234 shares of company stock worth $233,798. 4.10% of the stock is currently owned by company insiders.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.